A Disease Long Considered Difficult to Treat

Stage III non-small cell lung cancer (NSCLC) occupies an uncomfortable middle ground in oncology. These tumors have spread to regional lymph nodes but have not yet traveled to distant organs, making surgery impossible in many cases yet still potentially responsive to aggressive local treatment. For decades, the standard approach combined platinum-based chemotherapy with radiation — a regimen that improved outcomes compared to either treatment alone, but still left most patients facing disease recurrence within two years. The five-year survival rate hovered stubbornly around 15 to 30 percent, and clinicians recognized they needed a fundamentally different strategy to break through that ceiling.

What the PACIFIC Trial Set Out to Answer

The PACIFIC trial — formally known as a Phase 3, randomized, double-blind, placebo-controlled study — enrolled 713 patients with unresectable, locally advanced (Stage III) NSCLC whose disease had not progressed after platinum-based concurrent chemoradiation therapy. Patients were assigned in a 2:1 ratio to receive either durvalumab, a PD-L1 immune checkpoint inhibitor manufactured by AstraZeneca, or placebo, given intravenously every two weeks for up to 12 months. The central hypothesis was compelling: if chemoradiation increases PD-L1 expression on tumor cells and creates a more immunogenic tumor microenvironment, perhaps an immune checkpoint blockade delivered immediately afterward could prevent the microscopic disease that eventually seeds recurrence. Treatment began within one to 42 days of completing chemoradiation.

What the Data Showed

The results were striking enough to stop the oncology world in its tracks. Published in the New England Journal of Medicine in 2017 and updated in subsequent analyses, the PACIFIC trial demonstrated a median progression-free survival of 16.8 months in the durvalumab arm compared to 5.6 months in the placebo arm — a difference that translated to a hazard ratio of 0.52, meaning the risk of disease progression or death was cut nearly in half. Crucially, the overall survival data were equally compelling: the four-year overall survival rate was 49.6 percent with durvalumab versus 36.3 percent with placebo. These were not marginal gains. Patients in the durvalumab group were living meaningfully longer, and a subset appeared to experience durable, long-term disease control that older treatment regimens rarely produced. Importantly, the benefit was observed regardless of PD-L1 expression levels at baseline, though patients with higher PD-L1 expression derived the greatest benefit.

Establishing a New Standard of Care

Regulatory agencies moved swiftly. The U.S. Food and Drug Administration approved durvalumab for this indication in February 2018, and major guidelines from NCCAP, ESMO, and ASTRO were updated to reflect consolidation immunotherapy as the new standard of care following definitive chemoradiation in unresectable Stage III NSCLC. The PACIFIC regimen — chemoradiation followed by up to 12 months of durvalumab — is now the benchmark against which every subsequent treatment strategy in this setting is measured. The trial also prompted an important refinement in practice: patients tolerated the combination better when durvalumab was started earlier after completing radiation, leading most centers to aim for initiation within two to four weeks of completing chemoradiation.

What This Means for Patients Today

If you or a family member has been diagnosed with unresectable Stage III non-small cell lung cancer, the PACIFIC trial’s legacy is directly relevant to your care conversation. Any comprehensive treatment plan should now include a discussion of consolidation durvalumab after concurrent chemoradiation, assuming you have not progressed during that initial treatment phase. Ask your oncologist whether you are a candidate, what your PD-L1 expression status is, and what the monitoring plan looks like during the immunotherapy phase, since immune-related adverse events can affect the lungs, thyroid, and other organs and require early recognition. The PACIFIC trial did not cure stage III lung cancer, but it meaningfully altered the probability of long-term survival — and for patients facing this diagnosis, that shift in the odds is profoundly significant.